Cypherpunk Technologies (NASDAQ:CYPH) Director Thomas John Dietz Sells 20,000 Shares

Posted by Brian Himes on Aug 27th, 2026

Cypherpunk Technologies (NASDAQ:CYPH – Get Free Report) Director Thomas John Dietz sold 20,000 shares of the firm’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $1.72, for a total value of $34,400.00. Following the transaction, the director owned 132,500 shares in the company, valued at approximately $227,900. This trade represents a 13.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Cypherpunk Technologies Price Performance

CYPH traded up $0.26 on Thursday, hitting $1.89. 14,437,919 shares of the stock were exchanged, compared to its average volume of 3,801,312. Cypherpunk Technologies has a 12 month low of $0.27 and a 12 month high of $3.70. The firm has a market capitalization of $203.67 million, a price-to-earnings ratio of 3.37 and a beta of 0.09. The business has a 50-day moving average of $0.77 and a two-hundred day moving average of $0.81.

Cypherpunk Technologies (NASDAQ:CYPH – Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported $0.18 earnings per share for the quarter.

Analysts Set New Price Targets

Several research analysts have commented on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $1.60 target price on shares of Cypherpunk Technologies in a research note on Thursday. Weiss Ratings raised Cypherpunk Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 17th. Finally, Wall Street Zen raised Cypherpunk Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, July 4th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $1.60.

View Our Latest Analysis on Cypherpunk Technologies

Institutional Trading of Cypherpunk Technologies

Several hedge funds have recently modified their holdings of the stock. Millennium Management LLC bought a new stake in shares of Cypherpunk Technologies during the fourth quarter valued at approximately $37,000. LPL Financial LLC bought a new position in shares of Cypherpunk Technologies in the 4th quarter worth $38,000. Caitong International Asset Management Co. Ltd acquired a new stake in Cypherpunk Technologies in the 4th quarter valued at $44,000. Sequoia Financial Advisors LLC acquired a new stake in Cypherpunk Technologies in the 4th quarter valued at $56,000. Finally, HighTower Advisors LLC bought a new stake in Cypherpunk Technologies during the 4th quarter valued at $59,000. Institutional investors own 30.46% of the company’s stock.

Cypherpunk Technologies Company Profile

(Get Free Report)

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.

Receive News & Ratings for Cypherpunk Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cypherpunk Technologies and related companies with MarketBeat.com's FREE daily email newsletter.